This channel includes news on cardiovascular care delivery, including how patients are diagnosed and treated, cardiac care guidelines, policies or legislation impacting patient care, device recalls that may impact patient care, and cardiology practice management.
Discussions of AI governance may cause many an eye to glass over, but the discipline is as crucial to the ascent of AI in healthcare as big training datasets drawn from diverse patient populations.
For whatever reason, the grownups seem to get all the attention when talk turns to AI in healthcare. All the kiddos get to do is look on and listen in. Now comes a worthy little effort to balance the seesaw.
Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more.
The U.S. Food and Drug Administration has its hands full making sure medical AI products are safe, efficacious and trustworthy before they hit the market. The rise of ever-more-innovative iterations of the technology—not least generative AI—is only adding to the burden.
If a clinician you care about counts on AI to help make medical decisions, remind them: Tort law principles hold that doing so means risking liability should a patient sue over harm done.
All around the world, people are increasingly wise to the advance of AI. More than a few are growing ever more uneasy about it. And yet workers equipped with AI are both more productive and better at their jobs.
The avian influenza virus H5N1 has only turned up in two humans in the U.S., but its recent spread to dairy cattle has some experts on at least slightly elevated alert.
There have been a total of 11 incidents so far, including seven injuries and two deaths. Boston Scientific said the agent can still be used if operators follow specific instructions during lower GI bleed embolization procedures.
More than two-thirds of U.S. physicians have changed their minds about generative AI over the past year. In doing so, the re-thinkers have raised their level of trust in the technology to help improve healthcare.
Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more.
Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.
When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country.